We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Aclaris Therapeutics (ACRS - Free Report) shares ended the last trading session 6% higher at $5.64. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8% loss over the past four weeks.
Aclaris Therapeutics’ recent stock gains reflect improving investor confidence in the continued advancement of its pipeline programs. Its lead candidate, ATI-052, delivered positive data from the phase I study, demonstrating a favorable safety profile, potent and sustained target inhibition and the potential for once-every-three-month dosing. Phase Ib proof-of-concept studies in atopic dermatitis and asthma remain on track for top-line data in the second half of 2026, with a phase IIb asthma program planned for the fourth quarter of this year. Bosakitug (ATI-045) is being evaluated in a phase II study for moderate-to-severe atopic dermatitis, with data expected in the fourth quarter of 2026. In early August, modzatinib (ATI-2138), an oral ITK/JAK3 inhibitor, received Fast Track designation from the FDA for moderate-to-severe lichen planus, while Aclaris is advancing ATI-9494, an oral ITK inhibitor, toward an IND filing.
This specialty pharmaceutical company is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of -41.7%. Revenues are expected to be $1.28 million, down 61.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Aclaris, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACRS going forward to see if this recent jump can turn into more strength down the road.
Aclaris is part of the Zacks Medical - Drugs industry. NewAmsterdam Pharma Company N.V. (NAMS - Free Report) , another stock in the same industry, closed the last trading session 1.9% lower at $22.36. NAMS has returned -15.5% in the past month.
For NewAmsterdam Pharma Company N.V., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.5. This represents a change of -22% from what the company reported a year ago. NewAmsterdam Pharma Company N.V. currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris Therapeutics (ACRS - Free Report) shares ended the last trading session 6% higher at $5.64. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8% loss over the past four weeks.
Aclaris Therapeutics’ recent stock gains reflect improving investor confidence in the continued advancement of its pipeline programs. Its lead candidate, ATI-052, delivered positive data from the phase I study, demonstrating a favorable safety profile, potent and sustained target inhibition and the potential for once-every-three-month dosing. Phase Ib proof-of-concept studies in atopic dermatitis and asthma remain on track for top-line data in the second half of 2026, with a phase IIb asthma program planned for the fourth quarter of this year. Bosakitug (ATI-045) is being evaluated in a phase II study for moderate-to-severe atopic dermatitis, with data expected in the fourth quarter of 2026. In early August, modzatinib (ATI-2138), an oral ITK/JAK3 inhibitor, received Fast Track designation from the FDA for moderate-to-severe lichen planus, while Aclaris is advancing ATI-9494, an oral ITK inhibitor, toward an IND filing.
This specialty pharmaceutical company is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of -41.7%. Revenues are expected to be $1.28 million, down 61.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Aclaris, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACRS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Aclaris is part of the Zacks Medical - Drugs industry. NewAmsterdam Pharma Company N.V. (NAMS - Free Report) , another stock in the same industry, closed the last trading session 1.9% lower at $22.36. NAMS has returned -15.5% in the past month.
For NewAmsterdam Pharma Company N.V., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.5. This represents a change of -22% from what the company reported a year ago. NewAmsterdam Pharma Company N.V. currently has a Zacks Rank of #3 (Hold).